Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC reviews varenicline

The Midlands Therapeutic Review and Advisory Committee (MTRAC) has published a review of varenicline (Champix®) for smoking cessation.

Varenicline has been assessed as a Q3 drug, having a lower place in therapy and strong evidence. The reason given for the lower placing in therapy is the lack of comparative efficacy data versus nicotine replacement therapy. The overall advice is that varenicline is "suitable for prescribing in primary care for healthy adult smokers with no serious medical conditions (e.g. major depression, cardiovascular disease, uncontrolled hypertension)".

Action: As already discussed, nicotine replacement therapy remains the first line choice. Varenicline (and bupropion) are suitable alternatives where NRT treatment fails.

Share 'MTRAC reviews varenicline' on Email Share 'MTRAC reviews varenicline' on Delicious Share 'MTRAC reviews varenicline' on Digg Share 'MTRAC reviews varenicline' on Facebook Share 'MTRAC reviews varenicline' on Google+ Share 'MTRAC reviews varenicline' on reddit Share 'MTRAC reviews varenicline' on StumbleUpon Share 'MTRAC reviews varenicline' on Twitter

atomic-wealth

No Comments to “MTRAC reviews varenicline”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,527 spam comments.

atomic-wealth
fond-illness
summer